Tenaya Therapeutics (TNYA) Competitors

$0.79 -0.02 (-2.24%)

Closing price 04:00 PM Eastern

Extended Trading

$0.79 +0.00 (+0.51%)

As of 06:22 PM Eastern

TNYA vs. AMPH, SPRY, RLMD, SLDB, and AVTE

Should you buy Tenaya Therapeutics stock or one of its competitors? MarketBeat compares Tenaya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenaya Therapeutics include Amphastar Pharmaceuticals (AMPH), ARS Pharmaceuticals (SPRY), Relmada Therapeutics (RLMD), Solid Biosciences (SLDB), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Tenaya Therapeutics compare to Amphastar Pharmaceuticals?

Tenaya Therapeutics (NASDAQ:TNYA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 406.33%. Amphastar Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 34.91%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tenaya Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Tenaya Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Amphastar Pharmaceuticals	$719.89M	1.11	$98.09M	$1.66	10.94

In the previous week, Tenaya Therapeutics had 4 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 9 mentions for Tenaya Therapeutics and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.19 beat Tenaya Therapeutics' score of -0.19 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats Tenaya Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, ARS Pharmaceuticals had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 11 mentions for ARS Pharmaceuticals and 9 mentions for Tenaya Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.09 beat Tenaya Therapeutics' score of -0.19 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals presently has a consensus target price of $28.25, indicating a potential upside of 243.26%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 406.33%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tenaya Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.70	-$171.30M	-$2.01	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

ARS Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the broader market.

Tenaya Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Tenaya Therapeutics' return on equity of -80.56% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Summary

Tenaya Therapeutics beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 66.44%. Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 406.33%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Relmada Therapeutics' return on equity of -71.22% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

In the previous week, Tenaya Therapeutics had 9 more articles in the media than Relmada Therapeutics. MarketBeat recorded 9 mentions for Tenaya Therapeutics and 0 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.00 beat Tenaya Therapeutics' score of -0.19 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relmada Therapeutics	Neutral
Tenaya Therapeutics	Neutral

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

Relmada Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, meaning that its stock price is 177% more volatile than the broader market.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Tenaya Therapeutics beats Relmada Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Solid Biosciences?

Tenaya Therapeutics (NASDAQ:TNYA) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Solid Biosciences is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Solid Biosciences' return on equity of -73.42% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Solid Biosciences	N/A	-73.42%	-61.13%

Tenaya Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

In the previous week, Tenaya Therapeutics had 7 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for Tenaya Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.25 beat Tenaya Therapeutics' score of -0.19 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 406.33%. Solid Biosciences has a consensus price target of $16.36, suggesting a potential upside of 151.75%. Given Tenaya Therapeutics' higher probable upside, equities research analysts clearly believe Tenaya Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Tenaya Therapeutics beats Solid Biosciences on 8 of the 13 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Tenaya Therapeutics' return on equity of -80.56% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

In the previous week, Tenaya Therapeutics had 9 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 9 mentions for Tenaya Therapeutics and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Tenaya Therapeutics' score of -0.19 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Tenaya Therapeutics	Neutral

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market.

Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 406.33%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Tenaya Therapeutics beats Aerovate Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$171.43M	$3.36B	$6.34B	$12.29B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-1.68	19.01	20.94	25.47
Price / Sales	N/A	278.84	521.15	73.36
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	1.61	6.90	9.98	7.00
Net Income	-$90.60M	$24.23M	$3.55B	$335.16M
7 Day Performance	-15.51%	0.59%	0.42%	-0.29%
1 Month Performance	14.00%	-0.61%	0.00%	1.15%
1 Year Performance	78.69%	63.26%	34.99%	34.79%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	2.4578 of 5 stars	$0.79 -2.2%	$4.00 +406.3%	+69.7%	$171.43M	N/A	N/A	110
AMPH Amphastar Pharmaceuticals	4.1671 of 5 stars	$17.20 +2.0%	$24.50 +42.4%	-27.9%	$743.85M	$719.89M	10.36	1,976
SPRY ARS Pharmaceuticals	2.8625 of 5 stars	$7.30 -1.7%	$28.25 +287.0%	-45.6%	$737.31M	$84.28M	N/A	90	Earnings Report
RLMD Relmada Therapeutics	2.2742 of 5 stars	$6.34 -8.1%	$12.00 +89.3%	+1,101.0%	$723.74M	N/A	N/A	10	High Trading Volume
SLDB Solid Biosciences	2.6608 of 5 stars	$6.51 -5.9%	$16.36 +151.4%	+119.3%	$681.27M	N/A	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. AMPH, SPRY, RLMD, SLDB, and AVTE

How does Tenaya Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Tenaya Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Tenaya Therapeutics compare to Relmada Therapeutics?

Summary

How does Tenaya Therapeutics compare to Solid Biosciences?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. AMPH, SPRY, RLMD, SLDB, and AVTE

How does Tenaya Therapeutics compare to Amphastar Pharmaceuticals?

Do analysts prefer TNYA or AMPH?

Is TNYA or AMPH more profitable?

Do institutionals and insiders believe in TNYA or AMPH?

Which has preferable valuation & earnings, TNYA or AMPH?

Does the media prefer TNYA or AMPH?

Which has more risk & volatility, TNYA or AMPH?

Summary

How does Tenaya Therapeutics compare to ARS Pharmaceuticals?

Do institutionals and insiders have more ownership in SPRY or TNYA?

Does the media refer more to SPRY or TNYA?

Do analysts prefer SPRY or TNYA?

Which has higher valuation & earnings, SPRY or TNYA?

Which has more volatility & risk, SPRY or TNYA?

Is SPRY or TNYA more profitable?

Summary

How does Tenaya Therapeutics compare to Relmada Therapeutics?

Do analysts prefer RLMD or TNYA?

Is RLMD or TNYA more profitable?

Does the media favor RLMD or TNYA?

Which has stronger earnings and valuation, RLMD or TNYA?

Which has more risk and volatility, RLMD or TNYA?

Do insiders and institutionals hold more shares of RLMD or TNYA?

Summary

How does Tenaya Therapeutics compare to Solid Biosciences?

Which has stronger earnings & valuation, TNYA or SLDB?

Is TNYA or SLDB more profitable?

Which has more risk & volatility, TNYA or SLDB?

Does the media refer more to TNYA or SLDB?

Do analysts recommend TNYA or SLDB?

Do institutionals & insiders hold more shares of TNYA or SLDB?

Summary

How does Tenaya Therapeutics compare to Aerovate Therapeutics?

Is AVTE or TNYA more profitable?

Does the media refer more to AVTE or TNYA?

Which has better earnings & valuation, AVTE or TNYA?

Do institutionals & insiders believe in AVTE or TNYA?

Which has more risk & volatility, AVTE or TNYA?

Do analysts prefer AVTE or TNYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools